ASCO 2021 - Chicago - Chronic Myeloid Leukemia
NEWS
Potatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
June 5, 2021, Oncology Learning Network
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
June 5, 2021, Cancer Therapy Advisor
Dr Christopher Arendt on OPTIC Findings for Dose Optimization of Ponatinib in Patients With CP-CML
June 5, 2021, AJMC
Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting
May 20, 2021, businesswire
VIDEOS
SOME INTERESTING ABSTRACTS ABOUT CML
Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study.
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
Clinicopathological characteristics of CML in children and young adults.
First-line treatment outcomes of CML patients in a real-world data setting in Lebanon.
OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).
Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study.
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
Clinicopathological characteristics of CML in children and young adults.
First-line treatment outcomes of CML patients in a real-world data setting in Lebanon.
OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).